The Efficacy of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir with or without Ribavirin in Patients with Hepatitis C Undergoing Chronic Haemodialysis: A Single Center Experience
- Resource Type
- Authors
- Tansu Yamazhan; Nilay Danis; Ilker Turan; Zeki Karasu; Galip Ersoz; Hüsnü Pullukçu; Nalan Gülşen Ünal; Ulus Salih Akarca; Fulya Gunsar
- Source
- Viral Hepatitis Journal. 25:109-112
- Subject
- medicine.medical_specialty
Dasabuvir
business.industry
Ribavirin
Hepatitis C
medicine.disease
Single Center
Gastroenterology
Ombitasvir
chemistry.chemical_compound
chemistry
Paritaprevir
Internal medicine
medicine
Ritonavir
Chronic hemodialysis
business
medicine.drug
- Language
- ISSN
- 2147-2939
1307-9441
Objectives: Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir (PrOD) seems to be highly effective and safe in chronic haemodialysis (CHD) patients. We presented our experiences of treatment with PrOD in CHD patients.